Core Viewpoint - Nanwei Technology (688690) is experiencing growth driven by the booming GLP-1 peptide drug market, leading to increased investment in new drug research and production capacity by domestic and international pharmaceutical companies [2][3]. Group 1: Business Performance - The company's main revenue for Q1 2025 was 189 million yuan, a year-on-year increase of 22.39%, with a net profit attributable to shareholders of 29.22 million yuan, up 72.98% year-on-year [7]. - The gross profit margin for the chromatography filler business is high, accounting for approximately 60% of the company's revenue, which has improved overall profitability [4]. Group 2: Market Strategy - The company is focusing on the antibody new drug projects as a key area for replacing imported products, enhancing competitiveness through continuous R&D investment and product innovation [3]. - To address domestic competition, the company is building a comprehensive chromatography technology platform, providing integrated solutions to avoid price wars in single product categories [6]. Group 3: Mergers and Acquisitions - The acquisition of two instrument companies enhances the company's product line from chromatography fillers to protein purification equipment, improving business and product layout and achieving synergy in customer expansion and market sales [5]. Group 4: Future Outlook - The company is accelerating its overseas market layout and enhancing its overseas sales capabilities to increase application opportunities for its filler products among international clients [3][6].

Group 1 - Gan Li Pharmaceutical expects a net profit of 600 million to 640 million yuan for the first half of 2025, representing a year-on-year increase of 100.73% to 114.12%, driven by significant revenue growth and refined expense management [1] - The company successfully expanded its market share through two rounds of insulin procurement, indicating effective strategic positioning [1] - The anticipated performance increase is likely to boost investor confidence and enhance the company's valuation amid the normalization of centralized procurement in the pharmaceutical industry [1] Group 2 - Sinovac Biotech's special shareholder meeting resulted in the election of 10 new directors proposed by SAIF Partners, aimed at supporting the company's announced dividend distribution plan [2] - The new board members' commitment to closely collaborate with management is expected to stabilize investor confidence and unlock long-term value for shareholders [2] - SAIF Partners' involvement as a significant shareholder may enhance Sinovac's attractiveness and value in the capital market [2] Group 3 - Wohua Pharmaceutical anticipates a net profit of 37 million to 53 million yuan for the first half of 2025, reflecting a year-on-year increase of 233.89% to 378.27%, attributed to adapting to market changes and various marketing strategies [3] - The implementation of cost reduction and efficiency enhancement measures has effectively compressed costs and improved operating profits [3] - The strong performance is expected to bolster investor confidence in the company's future profitability and market appeal [3] Group 4 - Shanghai Pharmaceuticals projects a net profit of approximately 4.45 billion yuan for the first half of 2025, marking a year-on-year growth of about 52%, primarily due to the completion of acquiring a 10% stake in Shanghai Hutchison Pharmaceuticals [4] - The change in accounting treatment from equity method to subsidiary accounting is expected to enhance profitability and market competitiveness [4] - Investors are likely to view the company's strategic expansion positively, anticipating growth potential from this acquisition [4] Group 5 - Nanwei Technology expects a net profit of 61 million to 73 million yuan for the first half of 2025, representing a year-on-year increase of 35% to 62%, driven by a 20% growth in sales revenue of core products [5] - The anticipated growth is expected to enhance investor confidence in Nanwei's future development and market valuation [5] - The rapid development of the biopharmaceutical industry positions Nanwei to leverage its technological advantages and market expansion for further performance potential [5]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 Kroma sil ®： 以技术韧性助力全球制药产业升级 在现代药物生产工艺链中，色谱纯化是药物从粗品向高纯度终产品转化的关键分离步骤——通过固定相与流动相的相互 作用，实现目标成分与杂质的高效分离，直接决定目标成分的分离效率与终产品纯度。而作为这一环节的核心载体，色 谱填料更是至关重要。 当前，全球制药市场正经历剧烈变革：2型糖尿病、肥胖症等"富贵病"发病率在世界范围内迅速攀升，推动针对性治疗 药物，特别是减重类药物的需求快速增长；同时，随着专利悬崖逼近，本土药企加速入局，从"仿制药跟随"转向"创新 药突围"。在这场技术与市场的双重变革中，谁能为制药企业提供更高效、更稳定的色谱纯化解决方案？ 近日，仪器信息网专访了诺力昂（No u r y o n）个人护理与制药副总裁Da v i d Fr e i d i n g e r，围绕企业定位、产品技术、市 场 洞 察 及 中 国 战 略 展 开 深 度 交 流 。 其 旗 下 Kr oma sil® 从 1 9 8 8 年 开 始 就 致 力 于 ...

"这是用于细胞培养的一次性使用生物反应袋，属于技术门槛极高的柔性容器，用于生物制药工艺中的 细胞培养。此类产品在培养基、缓冲液等物料的配制转运，药液的储存与灌装，都会大量使用。"楚天 思优特工程师对《证券日报》记者表示，该产品采用了公司自主研发的11层生物复合膜材，具备很高的 生物安全性和极低的溶出物，其抗拉伸强度、抗穿刺性及气体阻隔性等物理性能，均大幅超越了进口同 类膜材。 在研发及放大生产阶段，楚天微球专注于层析填料技术。公司多款产品已通过美国FDA的DMF备案认 证，广泛应用于重组蛋白、疫苗、抗体、血液制品、基因/细胞治疗等生物大分子的分离纯化。楚天科 技董秘黄玉婷向《证券日报》记者举例说明："楚天微球已为东莞恒医生物科技有限公司提供了层析介 质及技术支持，助力其成功实现全球规模最大的3×30吨级发酵罐胶原蛋白量产。目前，楚天思优特与 楚天微球的产品，已能覆盖绝大多数创新药从小试、中试到产业化的全流程耗材需求。" 6月27日，来自近30个国家的超130位医药企业负责人齐聚楚天科技中国总部园区，开启为期3天的楚天 科技2025年首场总部工厂开放日活动，深度探访这家企业构建的"智慧医药工厂"生态体系。 当前 ...

聚光科技子公司普育科技在质谱仪领域取得突破，值得关注；生产端耗 材方面，培养基赛道的奥普迈近年来切入管线项目数量快速增长，填料 赛道的纳微科技和赛分科技质地优良，值得重点关注。 策略对话医药：生命科学服务 - 医药领域上游"卡脖子" 环节 20250703 摘要 生命科学服务板块是生物科学领域的基础，其自主可控至关重要，但目 前国产替代率不足 30%，高端科研仪器领域甚至为 0%，与赛默飞、丹 纳赫等国际巨头相比，国内企业规模明显偏小。 实现国产替代需多方面入手，包括加强基础科学教育以提高高端人才培 养，以及通过中央政府的政策支持，将高端科研仪器设备研发制造纳入 国家规划。 国产企业需与上下游产业链形成正反馈，通过低端市场反馈加速产品升 级，进而突破高端市场。同时，国际贸易环境的不确定性也推动跨国企 业加快本地化供应链布局，带动国内产业发展。 生产端耗材的国产替代已在部分细分领域取得进展，但因其为创新药商 业化生产必需且不易更换的原材料，替代过程需从早期阶段逐步推进， 培育周期较长。 新冠疫情期间进口原材料供应链短缺加速了国产工业生产端耗材的替代， 促使药企在早期研发阶段倾向使用国产耗材，并在临床三期和商业化 ...

Group 1: Industry Overview - Inner Mongolia is a significant energy and strategic resource base in China, with the largest proven coal reserves in the country, accounting for one-fourth of the national reserves, and the highest rare earth reserves [2][11] - In 2024, Inner Mongolia's coal production is expected to reach 1.29 billion tons, fulfilling a supply task of 830 million tons, which constitutes 34.5% of the national total [2] - The region is also facing challenges related to the large stockpile of coal-based solid waste, such as coal gangue and fly ash, which pose environmental risks [2] Group 2: Policy and Governance - The Inner Mongolia Autonomous Region has implemented various policies to support the construction of "waste-free cities," including regulations on solid waste pollution prevention and comprehensive ecological restoration plans [3][4] - The Ministry of Ecology and Environment has initiated a plan to promote the construction of approximately 100 "waste-free cities" during the 14th Five-Year Plan period, with Hohhot, Baotou, and Ordos included in the list [3] Group 3: Technological Innovation - The transformation of fly ash, a byproduct of the coal industry, into strategic resources like alumina has been achieved through collaboration between companies and universities, establishing a model project for utilizing non-bauxite ores [5] - Inner Mongolia Huineng Silicon-Aluminum New Materials Technology Co., Ltd. is set to produce 70,000 tons of casting aluminum-silicon and silicon-aluminum-titanium alloys annually, processing 200,000 tons of solid waste [6] Group 4: Environmental Restoration - Baotou City has successfully rehabilitated abandoned mining areas using local construction waste, agricultural straw, and livestock manure, significantly improving ecological conditions and increasing vegetation coverage from 15% to 82% [8] - The region has completed 172 construction projects funded by special funds for solid waste pollution prevention, enhancing waste reduction, resource utilization, and harmless treatment [9] Group 5: Economic Development - Baotou City is leveraging its advantages in rare earth and silicon industries to achieve resource conservation and efficient utilization, with a notable 12.6% reduction in industrial solid waste generation intensity expected in 2024 compared to 2023 [10] - Ordos City is focusing on ecological environment access for high-energy projects and promoting green building practices to reduce solid waste generation at the source [10]

半导体 半导体 2025 年 06 月 23 日 投资评级：看好（维持） 行业走势图 -38% -19% 0% 19% 38% 58% 77% 2024-06 2024-10 2025-02 半导体 沪深300 数据来源：聚源 相关研究报告 《半导体行业月度点评：下游回暖， 景气度改善可期—行业点评报告》 -2025.4.27 《关税反制政策落地，模拟芯片国产 化进程有望加速—行业点评报告》 -2025.4.7 《下游需求回暖+市场流动性注入，看 好 SoC 板块机会—行业点评报告》 -2024.10.9 半导体材料跟踪点评：盛合晶微进入辅导验收阶段， 关注先进封装材料投资机会 ——行业点评报告 陈蓉芳（分析师） 陈瑜熙（分析师） chenrongfang@kysec.cn 证书编号：S0790524120002 chenyuxi@kysec.cn 证书编号：S0790525020003 国产高端半导体封测龙头盛合晶微 IPO 进入辅导验收阶段 行 业 研 究 据证监会披露平台显示，盛合晶微 IPO 辅导状态变更为辅导验收。盛合晶微是 国内高端半导体封测龙头，核心业务聚焦中段硅片制造和三维集成先进封装环 节。 ...

Core Viewpoint - Nanwei Technology is positioned as a leading company in high-performance nano microsphere materials, with significant improvements in performance margins and growth opportunities in the chromatography filler sector due to import substitution and commercialization expansion [2][3][6]. Company Overview - Established in 2007, Nanwei Technology specializes in the R&D, mass production, sales, and application services of high-performance nano microsphere materials for various sectors including biomedicine and diagnostics [2]. - The company faced growth pressures in 2023 due to external macroeconomic changes, but has shown significant performance recovery since Q4 2024, with a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [2]. Market Opportunities - The global chromatography media market is projected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. The Chinese market is expected to grow from 11.2 billion yuan to 20.3 billion yuan in the same period, with a CAGR of 21.92% [3]. - Nanwei Technology is well-positioned to benefit from two major opportunities: import substitution and commercialization expansion. The company has developed a comprehensive range of chromatography fillers and media, making it a key player in the domestic market [3][4]. Import Substitution Opportunity - The chromatography filler and media industry has been historically dominated by foreign companies, with low domestic production rates. The rapid development of the domestic biomedicine industry and geopolitical tensions are driving the need for local alternatives [3]. - Successful project changes by downstream client Heng Rui Pharmaceutical provide a template for future import substitution projects, positioning Nanwei Technology as a leader in this transition [3]. Commercialization Expansion Opportunity - The usage of chromatography fillers and media increases with project phases, from early clinical trials to commercialization. Nanwei Technology has accumulated a growing number of clients and is nurturing numerous mid-to-late clinical projects, which are expected to yield significant returns [4]. Industry Chain Layout - Beyond its core business, Nanwei Technology is expanding its industry chain through a combination of self-built and acquired entities, including subsidiaries focused on chromatography instruments and diagnostic materials [5]. - Key subsidiaries include: - Fuli Instruments, a leader in domestic chromatography instruments, has made strides in gas and liquid chromatography [5]. - NAP Analysis, which focuses on high-quality laboratory chromatography consumables, achieving full domestic production [5]. - Saip Instrument, which develops precision purification equipment for large biomolecules, establishing itself as a leader in the domestic market [5]. Financial Forecast - Revenue projections for Nanwei Technology are 1 billion yuan in 2025, 1.24 billion yuan in 2026, and 1.55 billion yuan in 2027, with corresponding net profits of 141 million yuan, 221 million yuan, and 285 million yuan [6]. - The company is expected to maintain a strong growth trajectory, supported by its leadership in the chromatography filler and media sector and its strategic industry chain expansions [6].

色谱填料主业把握两大机遇，全产业链布局打开成长天花板 [Table_CoverStock] —纳微科技(688690)公司深度报告 [Table_ReportDate] 2025 年 06 月 06 日 [Table_CoverAuthor] 唐爱金 医药行业首席分析师 贺鑫 医药行业分析师 S1500523080002 S1500524120003 tangaijin@cindasc.com hexin1@cindasc.com [Table_StockAndRank] 纳微科技(688690) [Table_CoverReportList] 证券研究报告 公司研究 [Table_ReportType] 公司深度报告 投资评级 买入 [Table_Chart] 资料来源：聚源，信达证券研发中心 [Table_BaseData] 公司主要数据 收盘价（元） 21.80 52 周内股价波动区间 (元) 24.12-13.38 最近一月涨跌幅(％) -2.50% 总股本(亿股) 4.04 流通 A 股比例(％) 100% 总市值(亿元) 88.03 -40% -20% 0% 20% 40% 24/06 24/10 ...

色谱填料主业把握两大机遇，全产业链布局打开成长天花板 [Table_CoverStock] —纳微科技(688690)公司深度报告 [Table_ReportDate] 2025 年 06 月 06 日 [Table_CoverAuthor] 唐爱金 医药行业首席分析师 贺鑫 医药行业分析师 S1500523080002 S1500524120003 tangaijin@cindasc.com hexin1@cindasc.com [Table_CoverReportList] 证券研究报告 公司研究 [Table_ReportType] 公司深度报告 [Table_StockAndRank] 纳微科技(688690) 投资评级 买入 [Table_Chart] 资料来源：聚源，信达证券研发中心 [Table_BaseData] 公司主要数据 收盘价（元） 21.80 52 周内股价波动区间 (元) 24.12-13.38 最近一月涨跌幅(％) -2.50% 总股本(亿股) 4.04 流通 A 股比例(％) 100% 总市值(亿元) 88.03 -40% -20% 0% 20% 40% 24/06 24/10 ...